10-Q: AppYea Inc. Amends CFO Employment Terms Amidst Q2 Financial Results

AppYea Inc. released its Q2 2024 financial results, alongside an amended employment agreement for its CFO, Asaf Porat, which includes a reduction in salary and hours.

Summary

• AppYea Inc. reported a net loss of $1.063 million for the six months ended June 30, 2024, compared to a net loss of $631,000 for the same period in 2023.
• The company's revenue for the first six months of 2024 was $15,000, all from sales of the AppySleep wristband.
• Research and development expenses increased to $156,000 for the first six months of 2024, up from $16,000 in the same period of 2023.
• Sales and marketing expenses also saw a significant increase, reaching $157,000 for the first six months of 2024, compared to $2,000 in the same period of 2023.
• General and administrative expenses decreased to $499,000 for the first six months of 2024, down from $867,000 in the same period of 2023.
• The company's cash and cash equivalents stood at $158,000 as of June 30, 2024, with total liabilities of $2.615 million.
• AppYea has a stockholders deficiency of $2.142 million as of June 30, 2024.
• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• The CFO's amended employment agreement includes a reduction in salary to approximately $34,100 per annum and a waiver of options for 10,079,247 shares.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial losses, low cash reserves, and a going concern warning. While there are some positive developments, such as initial revenue generation and product launches, the overall sentiment is negative due to the company's precarious financial situation and dependence on external funding.

Positives

• The company generated $15,000 in revenue from product sales in the first half of 2024, indicating initial market traction.
• General and administrative expenses decreased, suggesting improved cost management.
• The company launched new IOS and Android versions of the AppySleep app during the third quarter of 2024.

Negatives

• The company reported a significant net loss of $1.063 million for the first six months of 2024.
• The company has a substantial stockholders deficiency of $2.142 million.
• The company's cash reserves are low at $158,000.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The CFO's salary was reduced, which could indicate financial constraints.
• The CFO waived a significant number of stock options, which could impact morale.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and limited operations.
• The company is dependent on external sources for financing its operations.
• There is no assurance that the company will be successful in obtaining adequate financing.
• The company may be required to implement cost reduction measures or delay development programs if it does not secure sufficient funding.
• The company faces a lawsuit that could have a material adverse effect on its business.
• The company's internal controls over financial reporting were deemed ineffective as of June 30, 2024.

Future Outlook

The company plans to file a 510(k) FDA submission for the AppySleep LAB app in 2025 and an FDA process for AppySleep PRO in 2026. The company also intends to establish its technology as the gold standard for targeted sectors over the next five years.

Management Comments

• Management believes that funds on hand will enable the company to fund operations through October 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Management is raising additional capital through debt and equity securities to continue funding operations.

Industry Context

The company operates in the growing market for anti-snoring and sleep apnea treatments, which is expected to reach $8.6 billion by 2028. The company's focus on AI-based solutions aligns with the trend towards improved diagnostics and outcomes in the healthcare industry.

Comparison to Industry Standards

• The company's revenue of $15,000 is very low compared to established companies in the sleep apnea and snoring treatment market.
• The company's significant net loss and negative cash flow are concerning compared to industry benchmarks for companies in the commercialization stage.
• The company's reliance on external funding and the going concern warning are not typical for companies with established products and market presence.
• The company's R&D and sales and marketing expenses are increasing, which is expected for a company in the growth phase, but the lack of revenue is a concern.
• The company's technology is based on a licensing agreement, which is common in the industry, but the terms of the agreement, including royalty payments and exit fees, could impact profitability.

Management Changes

Legal Proceedings

• A lawsuit was filed against the company's chairman and others in August 2022, alleging breach of partnership and loan agreements.
• The lawsuit was transferred to the economic department of the District Court in Tel Aviv.
• The parties are considering mediation before the ruling.

Related Party Transactions

• SleepX borrowed from Nexense Technologies USA. Inc., an entity majority owned by the company's chairman.
• The minority shareholder of Ta-nooma advanced a loan to Ta-nooma.
• The company converted outstanding amounts owed to its officers and directors into options.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost reduction measures or delays in development programs.
• Customers may be affected by the company's ability to continue operations and deliver products.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company plans to file a 510(k) FDA submission for the AppySleep LAB app in 2025.
• The company plans to pursue an FDA process for AppySleep PRO in 2026.
• The company intends to establish its technology as the gold standard for targeted sectors over the next five years.
• The company needs to raise additional capital to maintain operations.

Key Dates

Keywords

AppYea, SleepX, AppySleep, financial results, CFO, employment agreement, sleep apnea, snoring, wearable technology, biofeedback, FDA approval, capital raise, going concern